Member Info for RuckRover

" I think that we will see a marked uptake in interest post the Covidity RNS."
(Posted by Violindog)
Yes, if the CovidIty news is bad and the share drops 10p then I do expect a big uptake buying into Modi, Scib, Avidimab and Glymab at a hefty discount.

I'm looking forward to the next proactive interview introduced with a cheerleader squad performing to Jean-Michele's Oxygene music.

Ciaskin,
You may well be right, who knows what it was for. My thinking was "what has changed?"
Nothing as far as I know on Glymab but possibly it has on Covidity. If they sell it off outright, there would be no need for a separate company (if ever there was).
I'm surprised that they are winding up Zakari. They could have just kept it dormant - it would only cost the annual filing fee. That would have a least stopped us speculating what is was for and what's changed.

Possibly it could have but I think the appointment of a new chairman warrants a separate RNS rather than hidden in an interim financial update.

Cleaner,
Just because the vaccine's status is "designed" does not mean it's any good. We won't know that until the data has been analysed and results published. Even then, it will depend on what potential partners think of the results. Are they that much better than the competition?

As you say, the company have no intention to invest any more time on development so if the results are not extremely good or a partner can't be found then that's the end of the road for Covidity I'm afraid.

The winding up of Zakari might be a bit of a clue where this is going. It will be sold off for a nominal fee or scrapped (IMO). I'm not too worried about that, the dual in the crown is Moditope, ably backed up by Glymab.

Konar,
"strictly speaking we only have 2 trials in progress, not 3. Covidity trial has concluded."

No, the Covidity trial is still very much active. It is just that recruiting is complete that's all.
We still eagerly await results.

C11, I would hope he is exited.
We don't want the new chairman on his first day saying "I'm rather apathetic about the trials" (plural)

C11,
"Quite something from him."

Why, did no one tell him we have three trials in progress?

WTP,

I'm afraid that the "doom squad" are a figment of yours and a couple of others over active imagination. Everyone invested here wish Scancell success and are optimistic that will happen. Some people take a more circumspect view than others, that's all.
Like you, I managed to add earlier in the week and this morning sub 20p.

C11,
" It’s reasonable to think that the newsflow tap may well now be turned on in Feb."

Yes, quite reasonable. I remember when LD was appointed CEO there were several news releases over the following month.

He will do for me. Didn't expect to be able to buy sub 20p at this stage.

"Any chance it was deliberately confusing/unclear?"
I sincerely hope not. Manipulating the share price so your mates can buy would be a criminal offence. Besides, if this is going to multiple pounds per share, why would you be bothered about a few pence?

If the update was 19 out of 20 have shown a partial response, yes.
But that was never going to happen so, no.

This is the actual RNS statement...

"Based on the safety data analysed from Cohort 2, post-period the ModiFY trial was expanded at this dose for Modi-1 monotherapy in three tumour types. To date, 13 ovarian, two breast and three head and neck patients, including one in Cohort 3 in combination with a CPI, have been dosed with no safety issues. Modi-1 stimulates CD4 T cells which may directly impact tumour growth. However, in some patients these T cells may need to be protected by CPIs if the tumour environment is highly immunosuppressive."

Could someone post the RNS? I think the wording may need a closer inspection.

Crackin,

Perhaps Sounds of Silence would be just as apt?

I'm just in awe at the razor sharp wit on here.

Dalester,
Sorry, I wasn't meaning to be rude. I'm sure you have had am illustrious career in sales and in no way was I trying to belittle that. The point I was trying to make was that selling a potential life-saving treatment is very different to selling consumer products. There will be a selling of the science to the scientists, the commercial potential to the finance guys and the strategy to the bigwigs.
I was disappointed by the £5M upfront, I was hoping for £50M and at least £20M. Could we have got more? Who knows, certainly not any of is.
IMO

Dalester,

Have you thought of applying for The Apprentice? It's full of people with over exaggerated opinions of their abilities. You'd fit in well by the sound of it! :)

Matt,
I totally agree with the point by point analysIs but those were factually reported in the RNS.
Let's hope we have a gradual climb back to 28p while we wait for that Stonking RNS!